A clinical trial of the long acting antihistamic agent “Chlorpheniramine Nyscaps” was estimated on 37 cases of pruritic skin diseases, consisting of 10 cases of urticaria chronica, 2 of urticaria acuta, 3 of pruritus cutaneus universalis, 1 of erythema annulare centrifugum, 1 of erythrodermia, and 19 of eczema and/or dermatitis.
1. The daily dosage was 8∼16 mg, administrated orally once a day.
2. The duration of therapy was from 3 days to 7 days.
3. The result of clinical effect was evaluated as follows: it was markedly effective in 11 cases, and moderately in 17 cases, (consisting of 7 cases of urticaria chronica, 2 of urticaria acuta, 2 of pruritus cutaneus universalis, 1 of erythema annulare centribugum, 1 of erythrodermia and 14 of eczema and dermatitis).
4. The urinary and liver function tests were carried out in 7 cases given 16 mg of Chlorpheniramine Nyscaps daily for 14 days and no abnormal sign was observed.
5. Side effect was observed only in 2 cases. It was drowsiness in both cases.
We believe clinical administration of this drug will be favorably beneficial to treatment of pruritic skin diseases.
抄録全体を表示